Bicocca Open Archive

Logo unimib boa
SINICO, RENATO ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.556
EU - Europa 6.578
AS - Asia 3.481
SA - Sud America 119
Continente sconosciuto - Info sul continente non disponibili 32
AF - Africa 18
OC - Oceania 17
Totale 28.801
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.136
IT - Italia 1.377
IE - Irlanda 1.294
CN - Cina 1.265
SG - Singapore 1.146
RU - Federazione Russa 882
SE - Svezia 864
DE - Germania 642
HK - Hong Kong 525
GB - Regno Unito 402
CA - Canada 396
UA - Ucraina 311
FI - Finlandia 249
TR - Turchia 243
AT - Austria 183
FR - Francia 172
VN - Vietnam 80
BR - Brasile 74
DK - Danimarca 61
JP - Giappone 56
IN - India 47
ID - Indonesia 37
EU - Europa 30
NL - Olanda 29
ES - Italia 25
BE - Belgio 21
KR - Corea 21
MX - Messico 20
AU - Australia 15
CL - Cile 15
RO - Romania 14
IL - Israele 12
CO - Colombia 10
CZ - Repubblica Ceca 9
CH - Svizzera 8
GR - Grecia 7
IR - Iran 7
PE - Perù 7
EC - Ecuador 6
EG - Egitto 6
SA - Arabia Saudita 6
AR - Argentina 5
BG - Bulgaria 5
PK - Pakistan 5
PT - Portogallo 5
BD - Bangladesh 4
IQ - Iraq 4
NO - Norvegia 4
AE - Emirati Arabi Uniti 3
HU - Ungheria 3
PH - Filippine 3
PL - Polonia 3
SC - Seychelles 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
MA - Marocco 2
MU - Mauritius 2
NP - Nepal 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
TN - Tunisia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
DM - Dominica 1
DZ - Algeria 1
ET - Etiopia 1
HN - Honduras 1
IS - Islanda 1
KE - Kenya 1
KH - Cambogia 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MD - Moldavia 1
MN - Mongolia 1
MY - Malesia 1
NI - Nicaragua 1
PS - Palestinian Territory 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
VE - Venezuela 1
Totale 28.801
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.897
Woodbridge 2.065
Chandler 1.378
Dublin 1.232
Houston 1.224
Fairfield 1.043
Singapore 893
Dearborn 832
Wilmington 790
Jacksonville 783
Ashburn 722
Princeton 540
Hong Kong 513
New York 509
Frankfurt am Main 484
Seattle 407
Cambridge 360
Milan 351
Santa Clara 283
Nanjing 254
Lawrence 243
Altamura 211
Lachine 195
Vienna 182
Boardman 169
Beijing 145
Lissone 123
Shanghai 119
San Diego 110
Ottawa 101
Andover 83
Nanchang 76
Shenyang 70
Guangzhou 67
Toronto 67
Hebei 60
Norwalk 59
Falls Church 53
London 43
Jiaxing 42
Changsha 40
Los Angeles 40
Washington 39
Helsinki 38
Tianjin 38
Chicago 37
Mountain View 36
Jakarta 35
Jinan 35
Dong Ket 33
Hefei 25
Zhengzhou 25
Redmond 24
Hangzhou 22
Rome 22
Kunming 20
Philadelphia 20
Brussels 19
Munich 19
Pune 19
Florence 16
Kocaeli 16
Tokyo 16
Turin 15
Fremont 14
Lappeenranta 14
Tappahannock 13
Edmonton 12
Gwangmyeong 12
Sacramento 12
San Mateo 12
Brescia 11
Kilburn 11
São Paulo 11
Wuhan 11
Auburn Hills 10
Phoenix 10
Taizhou 10
Caronno Pertusella 9
Detroit 9
Palermo 9
Brno 8
Paris 8
San Francisco 8
Santa Monica 8
Verona 8
Dallas 7
Fuzhou 7
Genoa 7
Hanoi 7
Hounslow 7
Melbourne 7
Ningbo 7
Olbia 7
Padova 7
Paullo 7
Siena 7
Tel Aviv 7
Amsterdam 6
Berlin 6
Totale 21.753
Salva come PNG Salva come JPEG
Nome #
Modifications in peripheral-blood lymphocyte subpopulations induced by plasmapheresis and immunosuppressive drugs 390
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 340
Combined Plasmatic and Tissue Approach to Membranous Nephropathy-Proposal of a Diagnostic Algorithm Including Immunogold Labelling: Changing the Paradigm of a Serum-based Approach 308
MALDI imaging in Fabry nephropathy: a multicenter study 298
MALDI-MSI Approach to Renal Biopsies of Patients with Fabry Disease 269
MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy 264
Microscopic Polyangiitis 262
Kidney Involvement 236
Rituximab as maintenance treatment for systemic Lupus ErythematosusA multicentre observational study of 147 patients 236
Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases 226
135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS 222
Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient) 217
117. Prediction of Long-Term Evolutionary Profiles in Eosinophilic Granulomatosis with Polyangiitis (Churg– Strauss) Based on Baseline and Follow-Up Characteristics 198
Renal involvement in Churg-Strauss syndrome 191
162. Cluster analysis to explore clinical subclassification of eosinophilic granulomatosis with polyangiitis (churg–strauss) 190
Neutrophil Extracellular Traps (NETs) profiles in patients with incident SLE and lupus nephritis 189
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis 187
HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome 186
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy 185
Lack of IgA antineutrophil cytoplasmic antibodies in Henoch-Schönlein purpura and IgA nephropathy 184
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis 184
Aberrant N-glycosylation patterns related to serum IgG subclasses in Idiopathic membranous nephropathy 183
Eosinophilic granulomatosis with polyangiitis (churg-straus syndrome) 180
Systemic Vasculitis and Pregnancy: A Multicenter Study on Maternal and Neonatal Outcome of 66 Prospectively Followed Pregnancies 171
Systemic Vasculitis and Pregnancy: a Multicenter Study On Maternal and Neonatal Outcome of 43 Prospectively Followed Pregnancies 167
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 165
Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN) 162
Anti-Neutrophil Cytoplasmic Antibodies Positivity and Anti-Leukotrienes in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Monocentric Study on 134 Italian Patients 162
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 162
Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 157
Sneddon's syndrome: clinical and immunohistochemical findings 156
354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 156
Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): Planted antigens 155
[OP.4B.05] MIR-30A-3P EXPRESSION IN THE HEARTS OF DIABETIC RATS 152
RITUXIMAB AS MAINTENANCE THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS 149
Neutrophil Extracellular Traps in the Autoimmunity Context 149
255. Renal involvement in EGPA: a multicentre retrospective study of 63 cases 149
Multiple hepatic abscesses complicating continuous ambulatory peritoneal dialysis 146
Lymphocyte populations in the peripheral blood from patients with IgA nephropathy 145
Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain 145
The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy 144
Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study 144
Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity? 144
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis 143
Immunology of membranous nephropathy: From animal models to humans 140
Anticoagulant-related nephropathy: a pathological note 139
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 138
Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 137
FP165 Slowly progressive anca-associated glomerulonephritis: a multicentre study 137
Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study 137
ANCA-associated vasculitis in childhood: Recent advances 136
Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases 134
Polymeric IgA rheumatoid factor in idiopathic IgA mesangial nephropathy (Berger's disease) 132
Role and clinical significance of rheumatoid factors in glomerulonephritis 132
Outcome of Different Induction Regimens in Anca-Associated Glomerulonephritis According to the Histopathological Characteristics: the Reassess Study* 132
Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis [Position paper] 131
Clinical evaluation of a rapid immunofluorescence test (IIFT) for diagnosis of ANCA-associated vasculitis 130
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 130
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 128
alpha 1-Antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: genetic and clinical implications 128
Plasma-exchange and glomerulonephritis 128
Characterization of anti-myeloperoxidase antibodies in vasculitis 127
ANCA with specificity for lactoferrin in systemic lupus erythematosus (SLE) 127
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies 127
Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis 127
Clinical significance of autoantibodies to myeloperoxidase in vasculitic syndromes 126
Plasma-exchange in immunologically mediated glomerular diseases 124
T-lymphocyte subsets in primary and secondary glomerulonephritis 123
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 123
Specificity of anti-neutrophil cytoplasm antibodies (ANCA) in vasculitic syndromes 123
Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: A comparison of different assays 122
Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis 121
Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies/immune complex–Mediated membranoproliferative GN 120
Clinical significance of antineutrophil cytoplasmic autoantibodies with specificity for lactoferrin in renal diseases 120
Destructuring glomerular diseases with structured deposits: challenges in the precision medicine era 119
Spontaneous and pokeweed mitogen induced production of rheumatoid factor and immunoglobulins in type II essential mixed cryoglobulinaemia 116
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide 116
The subclavian vein as an emergency vascular access for hemodialysis and plasma exchange 115
Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome 115
Anti-C1q autoantibodies in lupus nephritis: Prevalence and clinical significance 115
B lymphocyte subpopulations and T-cell subsets in primary chronic glomerulonephritis 113
Infectious serologies and autoantibodies in wegener's granulomatosis and other vasculitides: Novel associations disclosed using the rad BioPlex 2200 113
L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 113
Anti-M-Type Phospholipase A2 Receptor (PLA2R) Antibodies: Diagnostic Performance and Clinical Significance in Idiopathic Membranous Nephropathy (IMN) 112
Effect of a continuous blood-cell separator and a polypropilene plasma filter on complement and platelet activation 112
ANCA-associated vasculitides (AAV) from the gender point of view 112
Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy: Aberrant IgG Glycoforms in Blood 111
Anti-endothelial cell antibodies in patients with Wegener's granulomatosis and micropolyarteritis 111
Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis 111
A reassessment of diagnostic criteria and treatment of idiopathic urticarial vasculitis: A retrospective study of 47 patients 110
Renal vasculitis 110
FP216Renal involvement in EGPA : a multicentre retrospective study of 63 cases 110
Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy 109
Detection of anti-IFI16 antibodies by ELISA: Clinical and serological associations in systemic sclerosis 109
Meningeal involvement in apparently ANCA-negative Wegener's granulomatosis: A role for PR3 capture-ELISA? [1] 108
Immunoglobulin heavy chain switch region gene polymorphisms in glomerulonephritis 108
Role of monocytes in extracapillary glomerulonephritis (gn) - histochemical-study in 15 patients 108
European consensus statement on the terminology used in the management of lupus glomerulonephritis 107
Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies 106
The kaleidoscopic manifestations of systemic vasculitis 105
Totale 15.321
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.851
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.851
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.181 0 0 0 0 0 595 508 230 216 145 365 122
2020/20213.779 118 120 469 425 235 388 519 375 381 294 184 271
2021/20222.909 153 295 405 193 210 197 143 152 134 167 311 549
2022/20234.857 662 1.283 345 373 420 819 48 227 410 40 146 84
2023/20243.713 127 127 134 146 526 951 762 94 328 59 58 401
2024/20253.052 483 899 322 374 782 192 0 0 0 0 0 0
Totale 30.108